The levels of MDM2 and RB are regulated by the CDKN2A gene, therefore deactivation of CDKN2A, which is common in T-ALL patients, leads to TP53 and RB pathway disturbances [56]. Here, CDKN2A is linked to acute lymphoblastic leukemia.